Lymph node-positive prostate cancer: Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy

Steven J. Buskirk, Thomas M. Pisansky, Elizabeth J. Atkinson, Steven E. Schild, Peter C. O'Brien, James T. Wolfe, Horst Zincke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

• Objective: To evaluate the outcome of patients with pathologic stage IV prostate cancer treated with androgen ablation plus external-beam radiation therapy. • Patients and Methods: Sixty consecutive patients treated between August 1986 and February 1995 with androgen ablation plus radiation therapy for stage IV (T1-4 N1 M0) adenocarcinoma of the prostate were selected for outcome analysis in this retrospective study. Bilateral pelvic lymphadenectomy was performed in 56 patients (93%). The 4 remaining patients had pelvic adenopathy on computed tomography, which was confirmed histologically in all patients. The median pretreatment prostate-specific antigen (PSA) level was 28.8 ng/mL (mean, 55 ng/mL; range, 0.1-428 ng/mL). All patients received radiation therapy to the prostate, and 29 (48%) had pelvic node radiation. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the PSA level. • Results: The median follow-up duration for surviving patients was 101.1 months (range, 20-134 months). Biochemical failure with (in 2 patients) or without (in 10 patients) clinically evident disease relapse was noted in 12 patients (20 %). Four additional patients (7 %) had clinical relapse without biochemical failure. Local recurrences were observed in 6 patients (10%), and this clinical impression was confirmed by biopsy in 4 patients. Thirteen patients (22%) died of causes related to prostate cancer. The biochemical relapse-free, clinical disease-free, overall, and cause-specific survival rates at 5 years were 82%, 84%, 76%, and 80%, respectively. • Conclusions: This observational case series of patients treated with the combination of external-beam radiation therapy and permanent androgen ablation for pathologic stage IV prostate cancer suggests that the addition of androgen deprivation therapy to radiation therapy may improve disease outcome. In the absence of randomized trial results, these observations may be beneficial in clinical decision making.

Original languageEnglish (US)
Pages (from-to)702-706
Number of pages5
JournalMayo Clinic Proceedings
Volume76
Issue number7
StatePublished - 2001

Fingerprint

Androgens
Prostatic Neoplasms
Radiotherapy
Lymph Nodes
Therapeutics
Recurrence
Prostate-Specific Antigen
Prostate
Lymph Node Excision
Adenocarcinoma
Survival Rate
Retrospective Studies
Tomography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Buskirk, S. J., Pisansky, T. M., Atkinson, E. J., Schild, S. E., O'Brien, P. C., Wolfe, J. T., & Zincke, H. (2001). Lymph node-positive prostate cancer: Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clinic Proceedings, 76(7), 702-706.

Lymph node-positive prostate cancer : Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. / Buskirk, Steven J.; Pisansky, Thomas M.; Atkinson, Elizabeth J.; Schild, Steven E.; O'Brien, Peter C.; Wolfe, James T.; Zincke, Horst.

In: Mayo Clinic Proceedings, Vol. 76, No. 7, 2001, p. 702-706.

Research output: Contribution to journalArticle

Buskirk, SJ, Pisansky, TM, Atkinson, EJ, Schild, SE, O'Brien, PC, Wolfe, JT & Zincke, H 2001, 'Lymph node-positive prostate cancer: Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy', Mayo Clinic Proceedings, vol. 76, no. 7, pp. 702-706.
Buskirk, Steven J. ; Pisansky, Thomas M. ; Atkinson, Elizabeth J. ; Schild, Steven E. ; O'Brien, Peter C. ; Wolfe, James T. ; Zincke, Horst. / Lymph node-positive prostate cancer : Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. In: Mayo Clinic Proceedings. 2001 ; Vol. 76, No. 7. pp. 702-706.
@article{e3cc8b9ba6dc48fca1e8baa6e5054f53,
title = "Lymph node-positive prostate cancer: Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy",
abstract = "• Objective: To evaluate the outcome of patients with pathologic stage IV prostate cancer treated with androgen ablation plus external-beam radiation therapy. • Patients and Methods: Sixty consecutive patients treated between August 1986 and February 1995 with androgen ablation plus radiation therapy for stage IV (T1-4 N1 M0) adenocarcinoma of the prostate were selected for outcome analysis in this retrospective study. Bilateral pelvic lymphadenectomy was performed in 56 patients (93{\%}). The 4 remaining patients had pelvic adenopathy on computed tomography, which was confirmed histologically in all patients. The median pretreatment prostate-specific antigen (PSA) level was 28.8 ng/mL (mean, 55 ng/mL; range, 0.1-428 ng/mL). All patients received radiation therapy to the prostate, and 29 (48{\%}) had pelvic node radiation. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the PSA level. • Results: The median follow-up duration for surviving patients was 101.1 months (range, 20-134 months). Biochemical failure with (in 2 patients) or without (in 10 patients) clinically evident disease relapse was noted in 12 patients (20 {\%}). Four additional patients (7 {\%}) had clinical relapse without biochemical failure. Local recurrences were observed in 6 patients (10{\%}), and this clinical impression was confirmed by biopsy in 4 patients. Thirteen patients (22{\%}) died of causes related to prostate cancer. The biochemical relapse-free, clinical disease-free, overall, and cause-specific survival rates at 5 years were 82{\%}, 84{\%}, 76{\%}, and 80{\%}, respectively. • Conclusions: This observational case series of patients treated with the combination of external-beam radiation therapy and permanent androgen ablation for pathologic stage IV prostate cancer suggests that the addition of androgen deprivation therapy to radiation therapy may improve disease outcome. In the absence of randomized trial results, these observations may be beneficial in clinical decision making.",
author = "Buskirk, {Steven J.} and Pisansky, {Thomas M.} and Atkinson, {Elizabeth J.} and Schild, {Steven E.} and O'Brien, {Peter C.} and Wolfe, {James T.} and Horst Zincke",
year = "2001",
language = "English (US)",
volume = "76",
pages = "702--706",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Lymph node-positive prostate cancer

T2 - Evaluation of the results of the combination of androgen deprivation therapy and radiation therapy

AU - Buskirk, Steven J.

AU - Pisansky, Thomas M.

AU - Atkinson, Elizabeth J.

AU - Schild, Steven E.

AU - O'Brien, Peter C.

AU - Wolfe, James T.

AU - Zincke, Horst

PY - 2001

Y1 - 2001

N2 - • Objective: To evaluate the outcome of patients with pathologic stage IV prostate cancer treated with androgen ablation plus external-beam radiation therapy. • Patients and Methods: Sixty consecutive patients treated between August 1986 and February 1995 with androgen ablation plus radiation therapy for stage IV (T1-4 N1 M0) adenocarcinoma of the prostate were selected for outcome analysis in this retrospective study. Bilateral pelvic lymphadenectomy was performed in 56 patients (93%). The 4 remaining patients had pelvic adenopathy on computed tomography, which was confirmed histologically in all patients. The median pretreatment prostate-specific antigen (PSA) level was 28.8 ng/mL (mean, 55 ng/mL; range, 0.1-428 ng/mL). All patients received radiation therapy to the prostate, and 29 (48%) had pelvic node radiation. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the PSA level. • Results: The median follow-up duration for surviving patients was 101.1 months (range, 20-134 months). Biochemical failure with (in 2 patients) or without (in 10 patients) clinically evident disease relapse was noted in 12 patients (20 %). Four additional patients (7 %) had clinical relapse without biochemical failure. Local recurrences were observed in 6 patients (10%), and this clinical impression was confirmed by biopsy in 4 patients. Thirteen patients (22%) died of causes related to prostate cancer. The biochemical relapse-free, clinical disease-free, overall, and cause-specific survival rates at 5 years were 82%, 84%, 76%, and 80%, respectively. • Conclusions: This observational case series of patients treated with the combination of external-beam radiation therapy and permanent androgen ablation for pathologic stage IV prostate cancer suggests that the addition of androgen deprivation therapy to radiation therapy may improve disease outcome. In the absence of randomized trial results, these observations may be beneficial in clinical decision making.

AB - • Objective: To evaluate the outcome of patients with pathologic stage IV prostate cancer treated with androgen ablation plus external-beam radiation therapy. • Patients and Methods: Sixty consecutive patients treated between August 1986 and February 1995 with androgen ablation plus radiation therapy for stage IV (T1-4 N1 M0) adenocarcinoma of the prostate were selected for outcome analysis in this retrospective study. Bilateral pelvic lymphadenectomy was performed in 56 patients (93%). The 4 remaining patients had pelvic adenopathy on computed tomography, which was confirmed histologically in all patients. The median pretreatment prostate-specific antigen (PSA) level was 28.8 ng/mL (mean, 55 ng/mL; range, 0.1-428 ng/mL). All patients received radiation therapy to the prostate, and 29 (48%) had pelvic node radiation. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the PSA level. • Results: The median follow-up duration for surviving patients was 101.1 months (range, 20-134 months). Biochemical failure with (in 2 patients) or without (in 10 patients) clinically evident disease relapse was noted in 12 patients (20 %). Four additional patients (7 %) had clinical relapse without biochemical failure. Local recurrences were observed in 6 patients (10%), and this clinical impression was confirmed by biopsy in 4 patients. Thirteen patients (22%) died of causes related to prostate cancer. The biochemical relapse-free, clinical disease-free, overall, and cause-specific survival rates at 5 years were 82%, 84%, 76%, and 80%, respectively. • Conclusions: This observational case series of patients treated with the combination of external-beam radiation therapy and permanent androgen ablation for pathologic stage IV prostate cancer suggests that the addition of androgen deprivation therapy to radiation therapy may improve disease outcome. In the absence of randomized trial results, these observations may be beneficial in clinical decision making.

UR - http://www.scopus.com/inward/record.url?scp=0034959989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034959989&partnerID=8YFLogxK

M3 - Article

C2 - 11444402

AN - SCOPUS:0034959989

VL - 76

SP - 702

EP - 706

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -